Nonalcoholic steatohepatitis (NASH), also referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH), has rapidly become a significant contributor to liver disease in the United States. The NASH market is growing at a substantial rate, driven by the increasing prevalence of the condition. According to the National Institute of Diabetes and Digestive and Kidney Diseases, while nonalcoholic fatty liver disease (NAFLD) remains common, only a fraction of these patients progress to NASH. As of 2023, the U.S. had the highest number of diagnosed NASH prevalent cases, with approximately 9.7 million individuals affected. Following closely behind were the EU4 nation...
